Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Liberty Biopharma Inc stock logo
LTY
Liberty Biopharma
C$2.00
+∞
C$2.00
C$0.06
C$2.74
C$21.54MN/A23,286 shs700 shs
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
C$0.47
-2.1%
C$0.42
C$0.35
C$0.66
C$52.89M0.8267,752 shs154,000 shs
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
$5.25
$5.36
$2.08
$12.80
$6.41M-1.66118 shsN/A
Valaris Limited stock logo
VAL
Valaris
$71.73
+1.3%
$69.74
$55.53
$78.92
$5.19B1.2890,464 shs531,425 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Liberty Biopharma Inc stock logo
LTY
Liberty Biopharma
0.00%0.00%0.00%0.00%0.00%
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
+9.09%+7.87%+29.73%-4.00%-12.73%
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
0.00%-17.19%-4.55%+75.00%+3,380.51%
Valaris Limited stock logo
VAL
Valaris
+3.74%+2.49%-3.95%+13.48%+24.12%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Liberty Biopharma Inc stock logo
LTY
Liberty Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
N/AN/AN/AN/AN/AN/AN/AN/A
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Valaris Limited stock logo
VAL
Valaris
3.1852 of 5 stars
3.51.00.00.01.81.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Liberty Biopharma Inc stock logo
LTY
Liberty Biopharma
N/AN/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
N/AN/AN/AN/A
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
N/AN/AN/AN/A
Valaris Limited stock logo
VAL
Valaris
3.00
Buy$100.0039.41% Upside

Current Analyst Ratings

Latest IXI, SIGY, NSCI, VAL, and LTY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
Valaris Limited stock logo
VAL
Valaris
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00
3/5/2024
Valaris Limited stock logo
VAL
Valaris
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.00
2/23/2024
Valaris Limited stock logo
VAL
Valaris
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$107.00 ➝ $105.00
2/14/2024
Valaris Limited stock logo
VAL
Valaris
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$106.00 ➝ $105.00
(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Liberty Biopharma Inc stock logo
LTY
Liberty Biopharma
N/AN/AC$0.00 per share2,000.00C$0.79 per shareN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
C$25.87M2.04C$0.05 per share8.93C$0.25 per share1.88
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
N/AN/AN/AN/A($2.80) per shareN/A
Valaris Limited stock logo
VAL
Valaris
$1.78B2.91$2.65 per share27.02$27.40 per share2.62

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Liberty Biopharma Inc stock logo
LTY
Liberty Biopharma
N/A-C$0.16N/AN/AN/AN/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
-C$16.96M-C$0.17N/AN/A-65.57%-47.87%-15.68%5/23/2024 (Estimated)
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
-$4.15M-$3.60N/AN/AN/AN/A-958.06%N/A
Valaris Limited stock logo
VAL
Valaris
$865.40M$11.436.286.91N/A44.93%3.81%1.62%8/6/2024 (Estimated)

Latest IXI, SIGY, NSCI, VAL, and LTY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024Q1 2024
Valaris Limited stock logo
VAL
Valaris
$0.40$0.35-$0.05$0.35$503.00 million$525.00 million      
2/21/2024Q4 2023
Valaris Limited stock logo
VAL
Valaris
$0.29$0.61+$0.32-$10.08$484.00 million$483.80 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Liberty Biopharma Inc stock logo
LTY
Liberty Biopharma
N/AN/AN/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
N/AN/AN/AN/AN/A
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
N/AN/AN/AN/AN/A
Valaris Limited stock logo
VAL
Valaris
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Liberty Biopharma Inc stock logo
LTY
Liberty Biopharma
8.19
0.12
0.12
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
71.36
1.52
1.11
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
N/A
0.03
0.02
Valaris Limited stock logo
VAL
Valaris
0.53
1.57
1.57

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Liberty Biopharma Inc stock logo
LTY
Liberty Biopharma
N/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
0.03%
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
10.01%
Valaris Limited stock logo
VAL
Valaris
96.74%

Insider Ownership

CompanyInsider Ownership
Liberty Biopharma Inc stock logo
LTY
Liberty Biopharma
N/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
7.11%
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
78.46%
Valaris Limited stock logo
VAL
Valaris
0.12%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Liberty Biopharma Inc stock logo
LTY
Liberty Biopharma
N/A10.77 millionN/ANot Optionable
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
249112.54 millionN/ANot Optionable
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
51.22 million264,000Not Optionable
Valaris Limited stock logo
VAL
Valaris
5,98572.41 million72.32 millionOptionable

IXI, SIGY, NSCI, VAL, and LTY Headlines

SourceHeadline
Benchmark Co. Reaffirms Their Buy Rating on Valaris (VAL)Benchmark Co. Reaffirms Their Buy Rating on Valaris (VAL)
markets.businessinsider.com - May 7 at 3:06 AM
What Analysts Are Saying About Valaris StockWhat Analysts Are Saying About Valaris Stock
benzinga.com - May 6 at 5:05 PM
Valaris’ 1Q Sets Positive Tone for OffshoreValaris’ 1Q Sets Positive Tone for Offshore
finance.yahoo.com - May 6 at 5:05 PM
Q2 2024 Earnings Forecast for Valaris Limited (NYSE:VAL) Issued By Capital One FinancialQ2 2024 Earnings Forecast for Valaris Limited (NYSE:VAL) Issued By Capital One Financial
americanbankingnews.com - May 6 at 1:22 AM
Benchmark Reaffirms Buy Rating for Valaris (NYSE:VAL)Benchmark Reaffirms Buy Rating for Valaris (NYSE:VAL)
americanbankingnews.com - May 5 at 5:02 AM
Valaris Limited (NYSE:VAL) Q1 2024 Earnings Call TranscriptValaris Limited (NYSE:VAL) Q1 2024 Earnings Call Transcript
msn.com - May 3 at 6:09 PM
Equinor starts drilling well on billion-barrel Argentina prospectEquinor starts drilling well on billion-barrel Argentina prospect
upstreamonline.com - May 3 at 12:44 PM
Valaris Ltd (VAL) Q1 2024 Earnings: Revenue Surpasses Estimates, Net Income DipsValaris Ltd (VAL) Q1 2024 Earnings: Revenue Surpasses Estimates, Net Income Dips
finance.yahoo.com - May 2 at 4:34 PM
Valaris Limited 2024 Q1 - Results - Earnings Call PresentationValaris Limited 2024 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 2 at 1:03 PM
Valaris (NYSE:VAL) Stock Rating Reaffirmed by BenchmarkValaris (NYSE:VAL) Stock Rating Reaffirmed by Benchmark
marketbeat.com - May 2 at 12:35 PM
Should You Add Valaris Limited (VAL) to Your Portfolio?Should You Add Valaris Limited (VAL) to Your Portfolio?
msn.com - May 2 at 9:27 AM
Retirement Systems of Alabama Purchases 43,368 Shares of Valaris Limited (NYSE:VAL)Retirement Systems of Alabama Purchases 43,368 Shares of Valaris Limited (NYSE:VAL)
marketbeat.com - May 2 at 6:15 AM
Valaris Reports First Quarter 2024 ResultsValaris Reports First Quarter 2024 Results
businesswire.com - May 1 at 6:27 PM
Valaris brings in $480m worth of new rig dealsValaris brings in $480m worth of new rig deals
splash247.com - May 1 at 1:18 PM
Valaris adds $480 million to its backlog thanks to hefty BP dealValaris adds $480 million to its backlog thanks to hefty BP deal
upstreamonline.com - May 1 at 1:18 PM
Valaris Issues Fleet Status ReportValaris Issues Fleet Status Report
businesswire.com - April 30 at 9:52 PM
Van ECK Associates Corp Reduces Position in Valaris Limited (NYSE:VAL)Van ECK Associates Corp Reduces Position in Valaris Limited (NYSE:VAL)
marketbeat.com - April 30 at 11:47 AM
UK offshore explorer hits out at political meddling hurting its growth plansUK offshore explorer hits out at political meddling hurting its growth plans
upstreamonline.com - April 30 at 3:20 AM
Esgian Week 17 Report: New Contracts for the North SeaEsgian Week 17 Report: New Contracts for the North Sea
marinelink.com - April 28 at 10:48 PM
Equinor rolls up its sleeves for imminent Argentina exploration wellEquinor rolls up its sleeves for imminent Argentina exploration well
upstreamonline.com - April 25 at 9:14 AM
Louisiana State Employees Retirement System Takes $1.21 Million Position in Valaris Limited (NYSE:VAL)Louisiana State Employees Retirement System Takes $1.21 Million Position in Valaris Limited (NYSE:VAL)
marketbeat.com - April 23 at 4:51 AM
John Fredriksen ally wins seat on board of potential takeover target International SeawaysJohn Fredriksen ally wins seat on board of potential takeover target International Seaways
tradewindsnews.com - April 18 at 10:48 PM
Valaris Limited (NYSE:VAL) Shares Sold by River Road Asset Management LLCValaris Limited (NYSE:VAL) Shares Sold by River Road Asset Management LLC
marketbeat.com - April 18 at 9:34 AM
Interocean announces UT technology demonstrationInterocean announces UT technology demonstration
zawya.com - April 16 at 8:33 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Liberty Biopharma logo

Liberty Biopharma

CVE:LTY
Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada.
Nanalysis Scientific logo

Nanalysis Scientific

CVE:NSCI
Nanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies. It serves pharmaceutical, security, biotech, nutraceutical, chemical, food, materials, medical, and education industries. The company is headquartered in Calgary, Canada.
Sigyn Therapeutics logo

Sigyn Therapeutics

OTCMKTS:SIGY
Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.
Valaris logo

Valaris

NYSE:VAL
Valaris Limited, together with its subsidiaries, provides offshore contract drilling services Gulf of Mexico, South America, North Sea, the Middle East, Africa, and the Asia Pacific. The company operates through four segments: Floaters, Jackups, ARO, and Other. It owns an offshore drilling rig fleet, which include drillships, dynamically positioned semisubmersible rigs, moored semisubmersible rig, and jackup rigs. It serves international, government-owned, and independent oil and gas. Valaris Limited was founded in 1975 and is based in Hamilton, Bermuda.